Glaucoma is a leading cause of irreversible blindness affecting approximately 60 million people globally 40 years of age and older. Glaucoma is a disease that cannot be ignored, and the need for significant changes in how we diagnose, manage, and treat must be examined and applied whenever possible.
The purpose of this study was to evaluate the efficacy and safety of subliminal cyclophotocoagulation using a 25% duty cycle diode laser (Supra 810, SubCyclo, Quantel Medical).
To analyse the results of subCyclo (subliminal transscleral cyclophotocoagulation) laser procedure for patients with glaucoma.
As a leading cause of irreversible blindness worldwide, glaucoma affects around 60.5 million people globally. Significant changes in diagnostic criteria, new therapies, and new tools for glaucoma management techniques have benefited individual patients
Quantel Medical y Ellex, dos marcas de Lumibird Medical, unidas con un objetivo: desarrollar tecnologías para el diagnóstico y tratamiento del ojo seco y las principales causas de ceguera en el mundo: glaucoma, cataratas, DMAE y retinopatía diabética.
"*" señala los campos obligatorios
